Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects.

Guler HP, Schmid C, Zapf J, Froesch ER

Proceedings of the National Academy of Sciences of the United States of America1 Apr 1989Cited by 168 (Europe PMC)

PMID2649897PMCIDPMC287020DOI10.1073/pnas.86.8.2868PepBankPUB-02649897

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
Blood glucose remained within normal limits during IGF-I infusion in healthy adults.
In plain wordsBlood sugar stayed within normal limits during IGF-I infusion in healthy adults.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableBlood glucose
Study
n = 2
Outcome group
Glycemic control · Metabolic and weight
Studied dose
20 micrograms/kg of body weight per hour · subcutaneous infusion · 6 daysAs given in this study (human).
Source sentences
Summary
Blood glucose and fasting insulin levels remained within normal limits and IGF-II levels were suppressed.
1 context sentence(design, population, supporting numbers)
Summary · context
Recombinant IGF-I was infused s.c. at a dose of 20 micrograms/kg of body weight per hour during 6 days in two healthy adult subjects.
Report a problemFND-0264989701
02HumanNon-randomized trialEfficacy outcome
Fasting insulin remained within normal limits during IGF-I infusion in healthy adults.
In plain wordsFasting insulin stayed within normal limits during IGF-I infusion in healthy adults.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableFasting insulin
Study
n = 2
Outcome group
Glycemic control · Metabolic and weight
Studied dose
20 micrograms/kg of body weight per hour · subcutaneous infusion · 6 daysAs given in this study (human).
Source sentences
Summary
Blood glucose and fasting insulin levels remained within normal limits and IGF-II levels were suppressed.
1 context sentence(design, population, supporting numbers)
Summary · context
Recombinant IGF-I was infused s.c. at a dose of 20 micrograms/kg of body weight per hour during 6 days in two healthy adult subjects.
Report a problemFND-0264989702
03HumanNon-randomized trialEfficacy outcome
IGF-I suppressed IGF-II levels in healthy adults.
In plain wordsIGF-I reduced IGF-II levels in healthy adults.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseIGF-II
Study
n = 2
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 micrograms/kg of body weight per hour · subcutaneous infusion · 6 daysAs given in this study (human).
Source sentences
Summary
Blood glucose and fasting insulin levels remained within normal limits and IGF-II levels were suppressed.
1 context sentence(design, population, supporting numbers)
Summary · context
Recombinant IGF-I was infused s.c. at a dose of 20 micrograms/kg of body weight per hour during 6 days in two healthy adult subjects.
Report a problemFND-0264989703
04HumanNon-randomized trialEfficacy outcome
IGF-I decreased fasting C-peptide in healthy adults.
In plain wordsIGF-I reduced fasting C-peptide in healthy adults.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseFasting C-peptide
Study
n = 2
Outcome group
Glycemic control · Metabolic and weight
Studied dose
20 micrograms/kg of body weight per hour · subcutaneous infusion · 6 daysAs given in this study (human).
Source sentences
Summary
In contrast to insulin, fasting C peptide levels were decreased.
1 context sentence(design, population, supporting numbers)
Summary · context
Recombinant IGF-I was infused s.c. at a dose of 20 micrograms/kg of body weight per hour during 6 days in two healthy adult subjects.
Report a problemFND-0264989704
05HumanNon-randomized trialEfficacy outcome
IGF-I suppressed GH secretion in healthy adults.
In plain wordsIGF-I reduced growth hormone secretion in healthy adults.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseGH secretion
Study
n = 2
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 micrograms/kg of body weight per hour · subcutaneous infusion · 6 daysAs given in this study (human).
Source sentences
Summary
GH secretion was also suppressed by IGF-I.
1 context sentence(design, population, supporting numbers)
Summary · context
Recombinant IGF-I was infused s.c. at a dose of 20 micrograms/kg of body weight per hour during 6 days in two healthy adult subjects.
Report a problemFND-0264989705
06HumanNon-randomized trialEfficacy outcome
During IGF-I infusion in healthy adults, creatinine clearance increased to 130% of preinfusion values.
In plain wordsDuring IGF-I infusion in healthy adults, a measure of kidney filtration increased above its pretreatment value.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseGlomerular filtration rate
Study
n = 2
Outcome group
Kidney function · Kidney and urinary
Studied dose
20 micrograms/kg of body weight per hour · subcutaneous infusion · 6 daysAs given in this study (human).
Measurements
Glomerular filtration rate (creatinine clearance)
130 % of preinfusion values
during IGF-I infusion
Source sentences
Summary
Glomerular filtration rate, as estimated by creatinine clearance, increased to 130% of preinfusion values during the IGF-I infusion.
1 context sentence(design, population, supporting numbers)
Summary · context
Recombinant IGF-I was infused s.c. at a dose of 20 micrograms/kg of body weight per hour during 6 days in two healthy adult subjects.
Report a problemFND-0264989706
07HumanNon-randomized trialEfficacy outcome
Total creatinine excretion remained unchanged during IGF-I infusion in healthy adults.
In plain wordsCreatinine excretion did not change during IGF-I infusion in healthy adults.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeCreatinine excretion
Study
n = 2
Outcome group
Kidney function · Kidney and urinary
Studied dose
20 micrograms/kg of body weight per hour · subcutaneous infusion · 6 daysAs given in this study (human).
Source sentences
Summary
Total creatinine and urea excretion remained unchanged.
1 context sentence(design, population, supporting numbers)
Summary · context
Recombinant IGF-I was infused s.c. at a dose of 20 micrograms/kg of body weight per hour during 6 days in two healthy adult subjects.
Report a problemFND-0264989707
08HumanNon-randomized trialEfficacy outcome
Total urea excretion remained unchanged during IGF-I infusion in healthy adults.
In plain wordsUrea excretion did not change during IGF-I infusion in healthy adults.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeUrea excretion
Study
n = 2
Outcome group
Kidney function · Kidney and urinary
Studied dose
20 micrograms/kg of body weight per hour · subcutaneous infusion · 6 daysAs given in this study (human).
Source sentences
Summary
Total creatinine and urea excretion remained unchanged.
1 context sentence(design, population, supporting numbers)
Summary · context
Recombinant IGF-I was infused s.c. at a dose of 20 micrograms/kg of body weight per hour during 6 days in two healthy adult subjects.
Report a problemFND-0264989708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.